Why is Emcure Pharma falling/rising?

As of 25-Sep, Emcure Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 1,318.60, which reflects a decrease of 10.9 points or 0.82%. The stock has shown a negative performance trend, having fallen after two consecutive days of gains. It is currently above its 200-day moving average but below its 5-day, 20-day, 50-day, and 100-day moving averages. Over the past week, the stock has decreased by 2.24%, and over the past month, it has fallen by 11.38%. Additionally, there has been a significant drop in investor participation, with delivery volume on 24 September falling by 57.92% compared to the 5-day average. Despite these challenges, the company has demonstrated high management efficiency with a return on capital employed (ROCE) of 20.99% and a low debt-to-EBITDA ratio of 0.53 times, indicating a strong ability to service its debt.
In the broader market context, Emcure Pharmaceuticals' recent performance has been slightly worse than the benchmark Sensex, which has declined by 2.23% over the same week. Year-to-date, Emcure's stock has decreased by 8.30%, while the Sensex has gained 3.87%. This underperformance may be contributing to the stock's downward pressure, as investors may be reacting to the broader market trends. Despite the company's positive financial results over the last four quarters, the combination of declining stock performance, reduced investor participation, and a challenging market environment has led to a cautious outlook for Emcure Pharmaceuticals.